IMPROVING THE SOLUBILITY OF A NEW CLASS OF ANTIINFLAMMATORY PHARMACODYNAMIC HYBRIDS, THAT RELEASE NITRIC OXIDE AND INHIBIT CYCLOXYGENASE-2 ISOENZYME